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Abstract
Background
With the emergence of new influenza virus strains that are resistant to current inhibitors
such as oseltamivir (anti-neuraminidase (NA)) and amantadine (anti-M2 proton channel),
influenza A viruses continue to be a serious threat to the public health worldwide.With this
in view, there is a persistent need for the development of broader and more effective vac-
cines and therapeutics. Identification of broadly neutralizing antibodies (bNAbs) that recog-
nize relatively invariant structures on influenza haemagglutinin (HA) stem has invigorated
efforts to develop universal influenza vaccines.
Aim
The current computational study is designed to identify potential flavonoid inhibitors that
bind to the contact epitopes of HA stem that are targeted by broadly neutralizing antibodies
(bNAb).
Method
In this study, we utilized the three-dimensional crystallographic structure of different HA sub-
types (H1, H2, H5, H3, and H7) in complex with bNAb to screen for potential broadly reactive
influenza inhibitors. We performed Quantitative Structure-Activity and Relationship (QSAR)
for 100 natural compounds known for their antiviral activity and performedmolecular dock-
ing using AutoDock 4.2 suite. Furthermore, we conducted virtual screening of 1413 bioas-
say hit compounds by using virtual lab bench CLCDrug Discovery.
Results
The results showed 18 lead flavonoids with strong binding abilities to bNAb epitopes of vari-
ous HA subtypes. These 18 broadly reactive compounds exhibited significant interactions
with an average of seven Hbonds, docking energy of -22.43 kcalmol−1, and minimum inter-
action energy of -4.65 kcalmol−1, with functional contact residues. Procyanidin depicted
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strong interactions with group 1 HAs, whereas both sorbitol and procyanidin exhibited signif-
icant interactions with group 2 HAs.
Conclusion
Using in silico docking analysis, we identified 18 bioactive flavonoids with potential strong
binding cababilities to influenza HA-stems of various subtypes, which are the target for
bNAb. The virtual screened bioassay hit compounds depicted a high number of Hbonds but
low interaction and docking values compared to antiviral flavonoids. Using structure-based
design and nanotechnology-based approaches, identifiedmolecules could be modified to
generate next generation anti-influenza drugs.
Background
Influenza A viruses (IAV) are a major cause of respiratory illness and result in significant mor-
tality and morbidity worldwide [1]. Although influenza vaccine has been available since 1938,
the vaccine content has to be assessed every year due to the continual change in hemagglutinin
protein (HA), which is the main target for neutralizing antibodies [2]. In addition to vaccines,
there are few drugs that are used to treat severe influenza infections [3]. Neuraminidase and
adamantanes inhibitors are two classes of anti-IAV drugs, approved to treat IAV infections by
targeting the viral components: Matrix proton channel (M2) and Neuraminidase glycoprotein
(NA) [2, 4]. However, H1N1 and H3N2 strains resistance to both drugs, especially to amanta-
dine, are prevalent worldwide [5]. In fact, up to 100% of the H1N1 subtypes were recorded
resistant to oseltamivir as of 2009 [5]. In 2009, the swine-origin pandemic H1N1 (pH1N1)
replaced the pre-2009 oseltamivir-resistant H1N1 variants and has now become one of the
dominant circulating seasonal influenza virus strains [5, 6]. Neuraminidase inhibitors are still
effective in treating circulating strains including adamantine-resistant one. Nonetheless, resis-
tant strains might sporadically emerge and spread worldwide considering the wide use of
inhibitor drugs and the unfortunate poor vaccine efficacy [7].
Broadly neutralizing antibodies (bNAb) that target conserved epitopes on HA stem have
been frequently isolated from phage-display libraries, plasma cells of immunized mice, or
memory B cells of immune donors [8]. Some of these antibodies are IAV group specific such
as CR6261 [9], F10 [10], and CR8020 [11], or with broader activity that target almost all IAV
strains such as CR9114 [12], FI6 [13], and many others [14, 15], such discoveries has opened
new doors toward passive immunotherapy and development of novel influenza vaccines with
broader activity [16].
We have reported on the structure-based design of a stabilized H1 stem nanoparticles (H1±
SS±np) that protect against heterogeneous highly pathogenic H5N1 virus in both mice and fer-
rets [17]. In the same study, we showed that passive transfer of immunoglobulin from H1±SS±
np±immunizedmice to naive mice conferred protection against H5N1 challenge, highlighting
the importance of conserved key structural elements as targets for vaccination and therapeutic
purposes [17]. Considering the restrictions and limitations of monoclonal antibodies (mAb)
use in therapeutics due to their cost, autoimmunity potentials, and the anti-mAb immune
response, these sites of vulnerability on HA-stem could be an ideal target for drug-based thera-
peutics in the form of small molecules [18].
Numerous approaches have been used to explore new antiviral drugs including in silico and
in vitro screening of known compounds for anti-IAV activity, as well as structure-based design
Computational screening for HA stem inhibitors
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of new antivirals drugs against specific viral molecules [19]. Presently, several flavonoids have
been identified with anti-IAV activity by inhibiting neuraminidase [20, 21]. Flavonoids possess
many biochemical properties, but the best-described property of almost every group of flavo-
noids is their capacity to act as antioxidants [22] and hapatoprotective activities [23]. In over-
all, flavonoids are exciting molecules combining an aromatic nature with numerous hydro-
philic groups. These aromatic properties play a significant role in protein-ligand and protein-
protein interactions [24, 25]. Further, the hydroxyl (OH) functional group (hydrophilic
nature) of flavonoids enables water displacement, which is a key determinant for ligand's
affinity [26]. Some of the flavonoids that exhibit anti-IAV activity are: phytochemicals ajoene,
baicalein, catechin, coumarin, menthol, theaflavin, ursolic acid, carvacrol, tinosporon, andro-
grapholide, and cucurmin [27±29].
In this study, we utilized the complex three-dimensional structure from PDB database of
various HA subtypes with bNAb to screen for strong flavonoid binders to conserved stem
region. We performed Quantitative Structure-Activity and Relationship (QSAR) for 100 natu-
ral compounds known for its antiviral activity and performed molecular docking using Auto-
Dock 4.2 suite. Furthermore, we conducted virtual screening of 1413 bioassay hit compounds
by using CLC Drug Discovery Workbench 3.02.
Methods
Structural models of influenza A stem from Group 1 and Group 2
PDB database was used to retrieve the X-ray crystal structure of various HA subtypes repre-
senting group1 and group 2 influenza viruses. This include H1-HA structure in complex with
CR6261 Fab (resolution of 2.2 Å; PDB# 3GBN;UniProtKB AC: Q9WFX3) (Figure A S1 Fig)
[30], H2 structure in complex with C179 Fab (resolution of 2.9Å; PDB# 4HLZ; UniProtKB
AC: C7S226) (Figure B S1 Fig) [3], H5 structure in complex F10 ScFv (resolution of 3.2Å;
PDB# 3FKU; UniProtKB AC: Q6DQ34) (Figure C S1 Fig) [31], H3 structure in complex with
CR8020 Fab (2.85Å of resolution; PDB ID# 3SDY; UniProtKB AC: A0A097PF39) (Figure D
S1 Fig) [32] and H7 structure in complex with CR9114 Fab (resolution of 5.75; Å PDB# 4FQV;
UniProtKB AC: Q6VMK1) (Figure E S1 Fig) [33]. Conserved epitopes of group 1 and group 2
HA structural models are shown in S1 Fig.
Protein preparation
PDB structures of H1, H2, H3, H5, and H7 to be docked with flavonoids were imported in
PDB format into AutoDock 4.2 and were assigned with specifically polar hydrogen for appro-
priate treatment of electrostatic docking. PDBQT file was used as coordinate files: includes
atom types and atomic partial charges [34]. Protein preparation using HA structure of H1N1
complex for virtual screening of small molecules was performed on CLC Drug Discovery
Workbench. The macromolecule (protein epitopes) were then refined with the Hbonds (HB)
assignment (water orientations, at neutral pH), and energy was minimized with MMFF94
force field [35]. The structure was then refined, making a minimization of the conformational
energy to generate 3D molecule structures on import [36]. Post-processing step was applied
for small molecules with no rotatable bonds with the energy window of 5 kcal/mol [37]. The
energy window was increased by 0.25 kcal/mol for each rotatable bond present in the mole-
cule. A grid for the protein was generated by using site around the centroids of selected resi-
dues in both AutoDock 4.2 and CLC Drug Discovery Workbench. The contact residues on H1
stem were: HIS8, HIS28, VAL30, ASN31, LEU32, ASP70, GLY71, TRP72, THR92, GLN93,
ILE96, ASN97, VAL103, ASN104, ILE107, THR100 (CR6261)[17]; on H2 stem: VAL18,
ASP19, GLY20, LYS38, TRP21, THR41, PHE45, ASP46, LYS43, GLN42, HIS38, VAL52,
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ILE56, PRO293, THR291, LEU292, ILE42, LYS40, THR318 (C179)[3]; on H5 stem HIS38,
PHE55, GLY20, HIS18, ASP19, TYR102, GLN42, ILE45, MET54, PHE55, THR41 (F10)[10];
on H3 stem GLU15, GLY16, VAL18, ASP19, LEU318, GLU325, GLN34, ALA35, ALA36,
ARG25, GLY33, THR32, ASN146, GLY150, GLU30 (CR8020)[38] and H7 ILE18, ASP19,
ALA36, LYS38, GLY20, TRP21, THR41, ILE45, GLN42, ASP46, THR49, SER40, LEU52,
ILE56, ALA292, ARG291, VAL293, ILE45 (CR9114)[12]. Contact residues on HA stem with
bNAb are depicted in S2±S6 Figs and summarized in S1 Table.
Ligand preparation
A total of hundred antiviral bioactive flavonoids were selected for in silico binding screening to
the bNAb epitope of the HA stem (S2 Table). The screening was done sequentially by testing
the binding to H1 subtype, and those with potential binding affinities were further screened
for binding to the rest of group 1 and then group 2 HA subtypes. ACD Chemsketch was used
to generate 3D structures of the natural molecules known for their antiviral properties [39].
1413 compounds were selected from PubChem database (Bioassay based) according to the
biological activity against IAV with IC50 1 nM (605 active compounds) and IC50 1 µM
(808 active compounds) for in silico docking analysis [40]. The 2D structures for screened
compounds were obtained from PubChem [41]. Ligand preparation in CLC Drug Discovery
was applied using freely available program ªBalloonº which is used for the 3D structure gener-
ation [42]. MedChem Designer tool was used to sketch 3D molecule and import as SMILES
strings format in CLC Drug Discovery Workbench [43].
Quantitative structure-activity relationship (QSAR)
A virtual model for property evaluation of chemicals was used to analyze the QSAR of selected
ligands to evaluate biological activities and physiochemical properties [44]. With the recent
advances in structure-based approaches in designing new drugs and vaccines, statistically-
based QSAR analysis helps in guiding optimization of generated product in terms of their bio-
logical and chemical properties. QSAR models predict biological activities based on chemical
structures. Mutagenicity model, physiochemical characters of ligands such as logP, carcinoge-
nicity model, developmental toxicity model, and ready biodegradability model, were deter-
mined for the selected flavonoids.
Docking protocol
Molecular docking studies for bioflavonoids were done by using AutoDock 4.2 MGL tools
[45]. Protein structures were prepared by creating PDBQT file that contains partial charges
and hydrogen atoms estimated by Gasteiger charges [46]. PDBQT file was prepared for ligand
via AMBER force field by adding hydrogen atoms. The contact residues were selected from the
string to generate grid parameters to target the potential binding site. Docking parameter file
was generated to run rescoring for higher accuracy [47]. Finally, each binding mode was
scored using the scoring function available in AutoDock and the best binding mode with the
corresponding interaction energy (IE) was identified. For comparative screening analysis,
1413 bioassay hit compounds were selected to screen for their binding to H1 HA stem by cre-
ating ligand based projects for all the chemical structures downloaded in the SDF file format.
CLC Drug Discovery Workbench was then used to generate ten best poses for each conforma-
tion of the best docking energy (DE) based on scoring functions. Docking wizard was used by
applying default MolDock optimizer algorithm with the following docking parameters includ-
ing 200 number of runs, maximum iterations 2000, crossover rate 0.90, scaling factor 0.50 and
RMSD thresholds for similar cluster poses were set as 1.00 [35]. The best-ranked compounds
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were selected on the basis of HB and DE and were visualized by using CLC Drug Discovery
Visualization tool.
Results
VEGA-QSAR profiling of screened products
Different biochemical properties of potential bioflavonoids were predicted by using VEGA-Q-
SAR analysis. Results evaluated by QSAR models could be effective to determine the chemical
properties of chosen compounds, thus, limiting the necessity of in vitro and in vivo evaluation
for only potential compounds. More than 65% of the chosen flavonoids were non-mutagen,
non-toxic, non-carcinogen and readily biodegradable. Predicted values for hundred bioflavo-
noids using VEGA-QSAR and their applicability domain analysis for various models have
been summarized in S3 Table. The log P value of the chosen flavonoids ranged from -0.01 to
7.05 log units.
Molecular interactions of flavonoids with group 1 subtypes: H1, H2, and
H5
In our in silico docking analysis, 100 natural bioactive flavonoids were initially docked with H1
subtype HA viral protein, from which, 46 flavonoids showed multiple HB and electrostatic
interactions to the contact residues of bNAb epitope. Five best binders with a maximum num-
ber of HB interaction included silybin, apigenin, morin, homoplantagin, and naringenin.
Five best conformations of best binders formed are illustrated in Fig 1. Flavonoid silybin
exhibited the best atomic interaction with H1 HA-stem residues HIS28, THR 40, ILE96, TRP
72, THR92, ASN97, THR100, VAL103, and ILE107, with minimum IE of -7.36 Kcal/mol and a
DE of -15.62 kcal/mol (Fig 2(A)). Apigenin and naringenin potentially formed five and three
HB with the alpha helix region of the H1 stem with IE of -6.36 Kcal/mol (DE: -27.32 Kcal/mol)
and -5.66 Kcal/mol (DE: -28.74 Kcal/mol), respectively (Fig 1B and 1E). Morin and homoplan-
tagnin formed only four HB but showed high interaction with an average of -7.56 Kcal/mol IE
Fig 1. Computational docking of flavonoids on H1 stem. Top five binders are shown: (a) Silybin, (b) Apigenin, (c) Morin, (d) Homoplantagnin and (e) Naringenin.
H1 stem region is depicted in ribbon with yellow color. HB interaction are denoted in dashed blue color.
https://doi.org/10.1371/journal.pone.0203148.g001
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Fig 2. Docking of three main flavonoids (silybin, procyanidin and sorbitol) to group 1 HA-Stem (H1, H2 and H5).
Analysis was done with AutoDock 4.2 Software. Analysis was done by considering the important parameters
including HB interaction, IE, and DE.A. Left panel shows H1 HA structure in light pink with CR6261 bNAb epitope
shown in dark blue. Middle panel shows interaction of silybin denoted in orange color to the bNAb epitope and right
panel shows anchoring residues between silybin molecule and stem epitope of bNAb. HB interaction is shown in black
color. B. Left panel shows H2 HA structure in light pink with Fab C179 bnAb epitope shown in dark blue. Middle panel
shows interaction of procyanidin to the bNAb epitope and right panel shows contact residues between procyanidin
Computational screening for HA stem inhibitors
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and -17.36 Kcal/mol DE (Fig 1C and 1D). Homoplantagnin formed marginally higher DE
with CR6261 epitope contact residues GLY71, THR92, ILE96, and VAL103 with an IE of -8.69
Kcal/mol, and DE of -18.65 Kcal/mol (Fig 1D). Other bioflavonoids such as amentoflavone,
baicalein, scutellarin, thioflavin and matteflavoside formed highest IE with only three HB,
with an average DE of -14.32 Kcal/mol (S4 Table). Minimum of four HB confirmation was
extended by sorbitol, epicatechin, procyanidin, quercetin, luteolin and honokiol with an aver-
age IE of -5.64 Kcal/mol and DE ranging between -5.63 Kcal/mol and -18.36 Kcal/mol. Most
of the screened bioflavonoids interacted repeatedly with H1 stem fusion peptide residues
ASN104 (helix region), and THR100 (loop region). Additionally, these bioflavonoids also
anchored several linear and discontinuous residues located on the H1 HA-stem. The HB
formed between each flavonoid compound and the H1 HA-stem with its DE, IE, and number
of residue interaction with labels are denoted in S4 Table.
Out of the forty-six bioflavonoid components that showed potential significant binding to
H1 HA-stem, only twenty-three compounds interacted with a minimum of three HB with H2
and H5 subtypes (S5 Table). The best five binders with H2 stem subtype included procyanidin,
Epigallocatechin gallate (EGCG), sorbitol, kuwanon L and morin, which fitted well in the
defined active pockets of the fusion peptide with a minimum IE values of -5.62 kcalmol−1,
-5.98 kcalmol−1, -7.54 kcalmol−1 and -5.85kcalmol−1, respectively and with average DE of
-20.45 kcalmol−1 (Fig 3). Procyanidin formed highest of nine HB interaction with binding res-
idues TRP21, THR41, PHE45, ASP46, THR291, LEU292, ILE42, LYS40, and THR318 of the
H2 stem in the beta strand (Fig 2(B)). EGCG, morin, and sorbitol also formed maximum num-
ber of eight HB and with an average DE of -19.67 kcalmol−1 (Fig 3B, 3C and 3E). Scutellarin,
molecule and stem epitope of bNAb. C. Left panel shows H5 HA structure in light pink with F10 bNAb epitope shown in
dark blue. Middle panel shows interaction of sorbitol to the bNAb epitope and right panel shows contact residues between
sorbitol molecule and stem epitope of bNAb.
https://doi.org/10.1371/journal.pone.0203148.g002
Fig 3. Computational docking of flavonoids on H2 stem. Top five binders are shown: (a) Procyanidin, (b) EGCG, (c) Sorbitol, (d) Kuwanon L and (e) Morin. H2 stem
region is depicted in ribbon with HA1 in pink and HA2 in yellow color. HB interaction are denoted in dashed blue color.
https://doi.org/10.1371/journal.pone.0203148.g003
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spirooligannone, salicin and 7-O-galloytricetiflavone exhibited six HB interaction at the C179
binding pocket with a minimum average IE greater than -7.22 kcalmol−1. Minimum of three to
five HB were made by hesperidin, glycyrrhiza flavonol A, silybin, isorhamnetin, baicalein, quer-
cetin, luteolin, honokiol, apigenin, isoliquiritigenin and salicylic acid, with DE between -8.41
kcalmol−1 to -16.36 kcalmol−1 (S5 Table). Interactions of the above flavonoids were also located
at beta strand (TRP21 to VAL52), beta-bridge (VAL18-GLY20), loop subdomains and bend in
distal HA region (ILE56, THR291-PRO293 and THR318) in the topological domain (S5 Table).
Most of the HB interactions from the 23 compounds were observed in the N-terminus of the
HA2 subunit, helix A, and beta strand, within the hydrophobic pocket incorporating residues
VAL18, ASP19, GLY20, TRP21, LYS38, THR41, GLN42, PHE45 and VAL 52 (S5 Table).
We next evaluated the top five binders interaction with H5 stem, epitope of the F10 bNAb.
salicin, scutellarin, EGCG, quercetin and sorbitol extended an average of seven HB with DE of
-11.34 kcalmol−1 (Fig 4). Among the five best binders, only sorbitol formed eight HB with res-
idues HIS38, PHE55, GLY20, HIS18, ASP19, TYR102, GLN42 and ILE45 with IE of
-7.22kcalmol−1 and DE of -12.45 kcalmol−1 (Fig 2(C)). EGCG was the second best binder,
extended seven HB interaction each with residues GLY20, HIS18, ASP19, TYR102, GLN42,
ILE45, and MET54 of the H5 stem and with IE of -7.36 kcalmol−1 and DE of 16.35 kcalmol−1
(Fig 4(C)). Salicin, scutellarin and quercetin formed an equal number of six HB and with IE
greater than -7.93 kcalmol−1 (Fig 4A, 4B and 4D). Residues at positions HIS18, ASP19,
GLY20, HIS38, and PHE55 within H5 stem, formed frequent interaction with all five best
compounds. The hydrophobic residues MET54 and PHE55 of the beta strand, which lies in
main-chain of the fusion peptide formed HB with scutellarin, silybin, glycyrrhiza flavonol A,
quercetin, apigenin, isoliquiritigenin, and salicin (S5 Table). Apart from the best binders, pro-
cyanidin, morin, scutellarin, silybin, isorhamnetin, quercetin, salicin, and amentoflavone
formed six HB with average IE and DE of -4.37 kcalmol−1 and -10.46 kcalmol−1, respectively
(S5 Table).
Fig 4. Computational docking study of flavonoids on H5 stem. Top five binders are shown: (a) Salicin, (b) Scutellarin, (c) EGCG, (d) Quercetin and (e) Sorbitol. H5
stem region is depicted in ribbon with HA1 and HA2 in blue color. HB interaction are represented in dashed blue color.
https://doi.org/10.1371/journal.pone.0203148.g004
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Molecular interactions with group 2 subtypes H3, and H7
Out of 23 bioflavonoid molecules that exhibited potential significant interaction with group1
HA-stems, only 18 flavonoids docked with more than four HB interactions and a minimum
energy to the H3 stem. H3 stem best binders consist of isorhamnetin, EGCG, naringenin, 7-O-
galloytricetiflavone and sorbitol (Fig 5). Both sorbitol (IE:-6.21 kcalmol−1 and DE:-24.45
kcalmol−1) and procyanidin (IE:-5.62 kcalmol−1 and DE:-13.45 kcalmol−1) extended a maxi-
mum of nine HB (S6 Table). Sorbitol bound with the same of bNAb CR9114 stem epitope resi-
dues VAL18, ASP19, LEU318, GLU325, GLN34, ALA35, ALA36, ARG25, GLY33 (Fig 6A),
while procyanidin bound with residues GLN34, ALA35, ALA36, ARG25, GLY33, THR32,
ASN146, GLY150, and GLU30 of the H3-stem epitope (S6 Table). Almost five HB were
extended by morin (IE:-6.66 kcalmol−1, DE:-16.31 kcalmol−1), apigenin (IE:-3.24 kcalmol−1,
DE:-11.45) and kuwanon L (IE:Ð3.32 kcalmol−1, DE:-9.99 kcalmol−1), in the alpha helix A
region within the hydrophobic pocket (S6 Table). Maximum number of HB were observed in
the outermost strand (HA2 residues GLU30±ALA36) of the 5-stranded β-sheet and the HA2
residues GLU15±ASP19 in the C-terminus portion of the fusion peptide. Of the 15 residues
that constituted the contact epitopes of CR8020 bNAb, only residue ASP19 was in common
interaction with most of the bioflavonoids including morin, scutellarin, apigenin, kuwanon L,
baicalein, naringenin, isoliquiritigenin, salicin, 7-O-galloytricetiflavone, sorbitol, luteolin and
amentoflavone (S6 Table).
Almost all the selected ligands that bonded with H3 also reacted to H7 in the docking analysis.
The top five predicted binders to H7 stem included sorbitol, procyanidin, 7-O-galloytricetiflavone,
epicatechin and scutellarin (Fig 7). Sorbitol also showed robust binding abilities to H7 stem simi-
lar to H3. It bound with bNAb contact residues LYS38, GLY20, TRP21, THR41, LEU52, ILE56,
and ALA292 with IE of -3.86 kcalmol−1 and DE of -24.45 kcalmol−1 (Fig 6B). Procyanidin and
7-O-galloytricetiflavone extended seven HB with an average of IE -2.66 kcalmol−1 (Fig 7B and
Fig 5. Computational docking study of flavonoids on H3 stem. Top five binders are shown: (a) Isorhamnetin, (b) EGCG, (c) Naringenin, (d) 7-O-galloytricetiflavon
and (e) Sorbitol. H3 stem region is depicted in ribbon with HA1 and HA2 in shaded green color. HB interaction are represented in dashed blue color.
https://doi.org/10.1371/journal.pone.0203148.g005
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Fig 6. Docking of flavonoids sorbitol to group 2 HA structures, H3 and H7. Analysis was done with AutoDock 4.2 Software. Analysis was done by
considering the important parameters including HB interaction, IE, and DE.A. Left panel shows H3 HA structure in light green with CR8020 bNAb epitope
shown in red. Middle panel shows interaction of sorbitol denoted to the bNAb epitope and right panel shows anchoring residues between sorbitol molecule and
stem epitope of bNAb. HB interaction is shown in black color. B. Left panel shows H7 HA structure in green with CR9114 bNAb epitope in red. Middle panel
shows interaction of sorbitol to the bNAb epitope and right panel shows contact residues between sorbitol molecule and stem epitope of bNAb.
https://doi.org/10.1371/journal.pone.0203148.g006
Computational screening for HA stem inhibitors
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7C). Morin, Kuwanon L, baicalein, quercetin, and amentoflavone principally formed five HB
interactions with both H3 and H7 subtypes (S6 Table). Only naringenin and isorhamnetin formed
three HB interaction with H7 stem while the rest 16 bioflavonoids formed almost five HB with the
H7 stem. Least IE was observed with apigenin (IE:-17.61 kcalmol−1, DE:-16.23 kcalmol−1) and
scutellarin (IE:-11.66 kcalmol−1, DE:-17.39 kcalmol−1) compared to all other flavonoids (S6
Table). Other flavonoids including luteolin, isoliquiritigenin, 7-O-galloytricetiflavone and iso-
rhamnetin exhibited high IE, average of -2.84 kcalmol−1 (S6 Table). Most of the screened 18 flavo-
noids exhibited binding at positions THR41, ASP46, THR49 and ILE56 of CR9114 bNAb epitope.
These results indicated that sorbitol, procyanidin, and 7-O-galloytricetiflavone could intensively
bind H3 and H7 stem epitope (Figs 5D, 5E, 7A, 7B and 7C). Heat map analysis of a number of HB
and IE of best 18 bioflavonoids against group 1 and group 2 IAV are shown in Fig 8.
Virtual screening study from bioassay hit compounds
We analyzed 1413 potential compounds from bioassay hit molecules for best binding capabili-
ties to CR6261 bNAb epitope on H1 HA stem. Ten compounds from PubChem, SID:
103512718, SID:160699960, SID:103619997, SID:103217472, SID:242620267, SID:242620266,
SID:242620268, SID:163315261, SID:163322216 and SID:160684110 extended best docking
confirmation (Fig 9). The above ten molecules depicted a high number of HB but low IE and
DE compared to flavonoids. Interestingly, the DE with bioassay hit molecules was lower (aver-
age:-7.45 kcalmol−1) compared to the best DE from bioflavonoids (average:-16.57 kcalmol−1)
(S7 Table). Maximum number of four HB were formed with HA2 contact residues as recog-
nized by alpha-helix of the CR6261 heavy chain. The contact residues of HA1 epitopes alpha-
helix (LEU42, LEU292, VAL40, and HA2 epitopes ILE56, VAL52, and THR49) exhibited most
of the binding (Fig 9). Interaction of binding with bioassay hit compounds were observed
between adjacent HA2 monomers and the N-terminus of the fusion peptide, embedded in the
hydrophobic pocket of the H1-HA stem. No interactions were observed at contact residues
Fig 7. Computational docking of flavonoids on H7 stem. Top five binders are shown: (a) Sorbitol, (b) Procyanidin, (c) 7-O-galloytricetiflavon, (d) Epicatechins and
(e) Scutellarin. H7 stem region is depicted in ribbon with HA1 and HA2 in shaded pink color. HB interaction are represented in dashed blue color.
https://doi.org/10.1371/journal.pone.0203148.g007
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conserved in the hydrophobic tip with HIS8 and HIS28 from HA1 and ASN31 and LEU32
from HA2 (S7 Table). Virtual screened molecular interaction values of ten bioassays hit com-
pounds docked with H1 stem region are depicted in Fig 9 with an average IE (-2.45 kcalmol−1)
and DE (-7.45 kcalmol−1) (S7 Table).
Discussion
Seasonal vaccines elicit neutralizing antibodies that recognize epitopes on the surface of the
highly variable head region of HA. Accordingly, the vaccine components are varied every year
in the hope of matching the circulating viral strains in the forthcoming influenza season. In
the past several years, many bNAb that recognize the highly conserved stem region that
encompasses the fusion peptide have been characterized [30]. The discovery of these antibod-
ies opened new doors toward the development of what so-called ªUniversal Influenza Vaccineº
that would protect from various subtypes and for a prolonged period of time [48].
On the other hand, with the continuous emergence of influenza strains that are resistant to
the currently available anti-viral drugs such as Amantadine (anti-M2 proton) and Oseltamivir
(Anti-NA), it becomes necessary to find alternative approaches to treat influenza. Here we
Fig 8. Heat map analysis of best 18 flavonoids binding to five HA subtypes while considering three main criteria: DE (Kcal/mol), HB and IE (Kcal/mol).
https://doi.org/10.1371/journal.pone.0203148.g008
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report on a molecular docking study to screen for natural compounds binding potentials to
the conserved influenza HA-stem that harbor the fusion peptide and is the prime target for
bNAb. Two separate structure-based computational analysis were done. The first involved
sequential docking analysis of 100 flavonoids for binding capabilities to the bNAb epitopes on
both group 1 and group 2 influenza HA, and the other involved screening of 1413 compounds
from bioassay hit molecules to identify their binding potentials to the H1-stem bNAb epitope.
Our analysis improves upon others in two main aspects: firstly, we focused on the conserved
epitopes which are the target of bNAb and secondly, we ran a sequential analysis by targeting
HA-stem from various influenza subtypes. The analysis also included QSAR evaluation of the
tested flavonoids to assess for their biological activities and physiochemical properties. This
enabled us to define a set of 18 broadly reactive compounds that exhibited significant HB
interactions, high DE, and minimum IE with functional contact residues.
Procyanidin were the best binders to group1 HA stem with an average of eight HB, IE of
-6.22 Kcal/mol and DE of -17.36 Kcal/mol. Second-inline potential binders for group1 HA
stem included sorbitol (HB:7, IE:-5.63 Kcal/mol, DE:-15.63 Kcal/mol), morin (HB:6, IE:-4.68
Kcal/mol, DE:-14.12 Kcal/mol), EGCG (HB:7, IE:Ð4.63 Kcal/mol, DE:-15.11 Kcal/mol), quer-
cetin (HB:5, IE:-3.63 Kcal/mol, DE:-14.63 Kcal/mol), kuwanon L (HB:6, IE:-3.09 Kcal/mol,
DE:-13.15 Kcal/mol) and salicin (HB:5, IE:-4.20 Kcal/mol, DE:-12.79 Kcal/mol). In alignment
with our findings, procyanidin have been recognized for their potent antiviral activity and
immunostimulatory effects against IAV (Neutralization IC50 of 16.2±56.5 µg/ml) [49]. Derken
et. al (2014) reported through in silico docking study the interaction of procyanidin with HA
receptor binding site, thus, indicating its potential role in inhibiting virus attachment to host
cells [50]. Further, procyanidin inhibited the growth of H1N1 clinical isolate was well as H1N1
mouse adapted strain, PR8 (IC50 of 2.2 µg/mL and 2.5 µg/mL, respectively) in vitro [51]. The
ability of this compound to bind both, the receptor binding domain as well as the conserved
stem epitope as demonstrated in our study, highlight its importance to develop next-genera-
tion broad anti-influenza drugs. The dimeric procyanidin has also shown significant inhibition
against other viruses such as herpes simplex virus type 1 (HSV-1) [52].
Fig 9. Virtual screening and molecular interaction with ten bioassay hit compounds on H1 stem region using CLC Drug DiscoveryWorkbench. This illustration
shows interaction of ligands with maximum number of HB with the active site on the stem epitopes. H1 stem region is depicted in ribbon with HA1 and HA2 in
pink color. HB interaction are represented in dashed black color. (A) SID:103512718 (blue color), (B) SID:160699960 (green color), (C) SID:103619997 (dark blue
color), (D) SID:103217472 (light blue color), (E) SID:242620267 (dark pale green color), (F) SID:242620266 (red color), (G) SID:242620268 (magenta color), (H)
SID:163315261 (pale blue color), (I) SID:163322216 (purple color), and (J) SID:160684110 (pale dark blue color).
https://doi.org/10.1371/journal.pone.0203148.g009
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Sorbitol was the best candidate for binding to group 2 IAV subtypes. Second-inline potential
binders for group 2 HA stem included procyanidin (HB:8, IE:-4.23 Kcal/mol, DE:-17.43 Kcal/
mol), EGCG (HB:6, IE:-3.76 Kcal/mol, DE:-11.56 Kcal/mol), epicatechin (HB:6, IE:-4.42 Kcal/
mol, DE:-12.56Kcal/mol), 7-O-galloytricetiflavone (HB:7, IE:-4.65 Kcal/mol, DE:-11.53 Kcal/
mol), and naringenin (HB:7, IE:-2.54 Kcal/mol, DE:-17.97 Kcal/mol). Although sorbitol was
reported earlier for its antiviral properties, it was recommended for use as a cryoprotectant dur-
ing lyophilization and freezing of several viruses such as a varicella-zoster virus, respiratory syn-
cytial virus, HSV, cytomegalovirus, and 17D Yellow fever vaccine [53]. Other efficient binders
for both group 1 and 2 IAV included EGCG, silybin, apigenin, naringenin, epicatechin, salicin,
quercetin, scutellarin, baicalein 7-O-galloytricetiflavone and amentoflavone. The antiviral activ-
ity of EGCG against influenza virus was reported for the first time in 1993 [54]. The green tea
molecule affected virus infectivity in cell culture and it was shown to agglutinate the influenza
viruses, preventing the virus from absorbing to MDCK cells [54]. Quercetin, apigenin, narin-
genin, and silybin were recently evaluated for their anti-HSV-1 and anti-parainfluenza activities
[55]. These compounds had high anti-HSV-1 activity with a minimum inhibitory concentration
between 0.1 and 0.8 ug/mL with silybin and quercetin being the most effective [55]. Scutellarin,
amentoflavone, and baicalein have been shown to inactivate different viruses at various levels
depending on the virus type, concentration and the cell type used in the assay [56].
Many strains of influenza, including the 2009 H1N1 influenza, are now resistant to com-
mercially available anti-influenza drugs such as Tamiflu (oseltamivir phosphate), Relenza
(zanamivir), Flumadine (rimantadine) and others [57, 58]. Flavonoids appear to be an effective
pharmacological expansion in the class of anti-viral complexes against IAV [59]. Although
these natural flavonoids are poorly soluble and rapidly degraded by metabolism, they can be
modified using structure-based design and nanotechnology-based approaches, to maintain
high affinity binding while exhibiting long half-life and strong solubility. Incorporation of
herbal drugs in the delivery system also gives aid to increase in solubility, enhance stability,
protect from toxicity, enhance pharmacological activity, improve tissue macrophage distribu-
tion, improve the bioavailability, sustain delivery and enhance the targeting capacity of flavo-
noids [60]. Various nano-vehicles based drug delivery platforms including solid lipid
nanoparticles [61], nanocarriers [62], nanocapsules [63], biodegradable nanoparticles [64],
polymeric nanoparticles [65], polymeric micelles [66], dendrimers [67] and microemulsions
[68] are emerging as viable alternatives that showed to selectively deliver flavonoids [57]. Cer-
tain dietary flavonoids such as quercetin [69], EGCG [70], and lycopene [71] have reached
Phase I clinical trials for their pharmacological effects [72].
In conclusion, we identified 18 bioflavonoids capable to bind HA stem from different sub-
types, thus could avert the HA conformational changes required to carry out its membranes
attachment activity. Identified molecules from this study may be a new class of potent agents,
but further confirmation in in vitro and in vivo is essential to design highly interactive univer-
sal IAV therapy.
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